Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST

Takayuki Katsuura, Kazuhiro Kitajima, Masayuki Fujiwara, Tomonori Terada, Nobuhiro Uwa, Kazuma Noguchi, Hiroshi Doi, Yukihisa Tamaki, Rika Yoshida, Tatsuya Tsuchitani, Masahiro Fujita, Koichiro Yamakado

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Purpose: To evaluate therapeutic response to chemoradiotherapy and prediction of recurrence and death in patients with head and neck squamous cell carcinoma (HNSCC) using Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST). Materials and methods: Forty-two patients (mean 63.4, range 20–79 years) with nasopharyngeal (n = 10), oropharyngeal (n = 13), hypopharyngeal (n = 11), or laryngeal (n = 8) cancer underwent fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) before and approximately 3 months (mean 95.0, range 70–119 days) after undergoing concurrent chemoradiotherapy. The effect of PERCIST regarding progression-free survival (PFS) and overall survival (OS) was examined using log-rank and Cox methods. Results: Complete metabolic response (CMR), partial metabolic response (PMR), stable metabolic disease (SMD), and progressive metabolic disease shown by PERCIST were seen in 30 (71.4%), 9 (21.4%), 3 (7.1%), and 0 patients, respectively. Fourteen (33.3%) developed recurrent disease (median follow-up 27.2, range 8.7–123.1 months) and 9 (21.4%) died (median follow-up 43.6, range 9.6–132.6 months). Furthermore, 4 (13.3%) of 30 patients with CMR developed recurrence, while 7 (77.8%) of 9 with PMR and all 3 (100%) with SMD developed recurrence. Two (6.7%) of 30 patients with CMR, 4 (44.4%) of 9 with PMR, and all 3 (100%) with SMD died. Patients who achieved CMR showed significantly longer PFS and OS as compared to those who did not (PMR and SMD) (both, p < 0.0001). Conclusion: PERCIST is useful for evaluating therapeutic response to chemoradiotherapy and predicting recurrence and death in HNSCC patients.

Original languageEnglish (US)
Pages (from-to)453-462
Number of pages10
JournalAnnals of Nuclear Medicine
Volume32
Issue number7
DOIs
StatePublished - Aug 1 2018

Keywords

  • FDG-PET/CT
  • Head and neck squamous cell carcinoma (HNSCC)
  • PERCIST
  • Prognosis
  • Treatment response

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST'. Together they form a unique fingerprint.

Cite this